Gap junctional intercellular communication is inhibited in response to tumor promoters and oncogene transformation, suggesting that loss of this function is an important step in tumor formation. To elucidate the molecular mechanisms responsible for this inhibition, we examined the expression of gap junction proteins and mRNA in mouse primary keratinocytes after treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) and/or ras transformation. During normal cell growth, keratinocytes express the a, (connexin 43) and P (connexin 26) proteins. Within 5 min of TPA treatment, the al protein became rapidly phosphorylated on serine residues and its expression was dramatically reduced by 24 h. The 12 protein, after an initial increase in expression, was also significantly reduced 24 h after treatment with TPA. ras transformation caused changes similar to those induced by TPA. The al protein underwent an increase in serine phosphorylation, although its expression declined only slightly, while 012 expression was greatly reduced.
Gap junctions are transmembrane channels that directly link the cytoplasms of adjacent cells (3, 21, 35) . While gap junctions from different tissues are not identical, they share a basic structural organization. Six protein subunits, termed connexins, form a hemichannel or connexon in the plasma membrane of one cell, and connexons from adjacent cells then pair to generate a complete channel. Gap junctional intercellular communication (GJIC) mediates transfer of ions and low-molecular-weight metabolites (<1,000 daltons; 35) which are thought to regulate growth and differentiation, as well as maintain normal tissue homeostasis (34, 42) . Antibodies to gap junction proteins were found to interfere with development when injected into amphibian embryos (51) .
Many lines of evidence suggest that GJIC plays a role in tumor formation. Tumor promoters have been shown to inhibit GJIC both in vitro (37, 54) and in vivo (26, 27) , and the ability to communicate is lost in many types of tumor cells (53) . Transformation of cells by the src, ras, myc, and neu oncogenes (2, 5, 7, 12, 16 ) also leads to suppression of GJIC, showing that a decrease in GJIC is a common result of oncogene activation.
Several connexins from different tissues have been cloned in recent years (4, 20, 24, 31, 41, 58) , yielding much information concerning the structure, membrane topology, and tissue distribution of the gap junction proteins. However, relatively little is understood about the molecular mechanisms that control GJIC in both normal and transformed cells. Modulation of junctional communication by the src oncogene and retinoic acid was shown to be associated with posttranslational modifications of the gap junction proteins (11, 44, 49) . Retinoic acid treatment results in increases in both GJIC and phosphorylation of ot (connexin 43; 44) , while inhibition of GJIC by src correlates with tyrosine phosphorylation of ot (11, 18, 49) .
Mouse primary keratinocytes provide an ideal system for studying the role of GJIC in carcinogenesis. Cells of primary origin have not yet undergone the many changes which occur during establishment in culture and are amenable to the study of transformation in vitro, in vivo, and after transplantation onto an animal (see, for instance, references 6, 15, 23, 36a, 45, and 56) . Gap junctional communication in this system is dramatically reduced after treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) or transformation with the ras oncogene (12) . Furthermore, treatment of ras-transformed primary keratinocytes with TPA completely abolishes GJIC (12) . The similar and synergistic effects of ras and TPA on GJIC suggest that inhibition ofjunctional communication represents an initial step in keratinocyte transformation.
In this study, the molecular mechanisms by which TPA and ras regulate GJIC in mouse primary keratinocytes were investigated. These agents affected both synthesis and modification of the gap junction proteins. Inhibition of GJIC by TPA or the ras oncogene correlated with both phosphorylation of ao (connexin 43) and a decline in a, and 12 (connexin 26) expression. The effects of TPA and ras on a, expression were additive; TPA treatment of ras-transformed cells resulted in enhanced a, phosphorylation and marked reduction of its protein, to a level much lower than that generated by either agent alone. Inhibition of GJIC by ras or TPA in other cell types may occur through similar effects on the production and processing of gap junction proteins. 32P-labelled samples and similarly treated unlabelled samples were electrophoresed on an SDS-polyacrylamide gel and transferred to an Immobilon membrane (Millipore Corp., Bedford, Mass.). The unlabelled portion of the blot was probed with a1 antibodies and '25I-labelled protein A as described above and aligned with the portion of the blot containing the 32P-labelled samples. Regions of the blot corresponding to the 44-and 46-kDa a, species were excised, rehydrated in methanol, washed twice in distilled water, hydrolyzed with HCI (110°C, 2 h), and lyophilized (29) . Individual 32P-labelled phosphoamino acids were resolved by two-dimensional thin-layer electrophoresis as previously described (10) .
MATERIALS AND METHODS

Cells
Immunofluorescence. Keratinocytes were fixed in methanol (5 min at -20°C), washed with PBS, and incubated in 100% acetone for 7 min at -20°C. Cells were then washed with PBS, incubated with preimmune serum or the a1S antibody diluted 1:75 or 1:100 in PBS for 1 h at 37°C in a humidified box, and extensively washed with PBS. Fluorescein isothiocyanate-conjugated F(ab')2 goat anti-rabbit immunoglobulin G (Cappel Laboratories, West Chester, Pa.) Phosphatase digestion of a,. a1 protein was immunoprecipitated from untreated and TPA-treated (100 ng/ml, 2 h) keratinocytes as described above, except that samples were washed twice with phosphatase reaction buffer (50 mM Tris-Cl [pH 8 .0], 10 mM MgCl2, 150 mM NaCl) supplemented with 0.1% Triton X-100-0.05% SDS-2 m-M phenylmethylsulfonyl fluoride; suspended in 20 pd of phosphatase reaction buffer containing 1% SDS, 1% 2-mercaptoethanol, and 2 mM phenylmethylsulfonyl fluoride; and heated (60°C, 3 min). Samples were then divided in half (10 ,ul) electrophoresed on 12.5% acrylamide-0.10% bis SDS gels and analyzed by immunoblotting as described above.
RESULTS
Effects of TPA on gap junction protein expression and modification. In our initial experiments, we found that murine primary keratinocytes express both the a1 (4) and P2 (58) gap junction genes but not the 1 gene (31, 41; data not shown). To elucidate the molecular mechanism responsible for inhibition of GJIC by phorbol esters, the gap junction protein profile was examined following exposure to TPA. a1 protein is posttranslationally phosphorylated in several cell types to two more slowly migrating forms of 44 and 46 kDa (the nonphosphorylated form is 42 kDa; 11, 38, 39). In proliferating keratinocytes, the predominant form of a1 protein migrated as a 42-kDa species (Fig. 1A) . The 44-and 46-kDa forms were present as minor fractions of a1 protein.
Following treatment with 10 ng of TPA per ml for 1 to 2 h, the higher-molecular-weight species (44 and 46 kDa) increased relative to the 42-kDa protein, resulting in equal distribution of at1 among the three forms (Fig. 1A) . By 4 to 8 h after treatment, most of the a1 protein was converted back to the 42-kDa species. After 24 h, there was a dramatic reduction in the total amount of the protein (Fig. 1A) .
Gap junction protein localization was examined before and 2 h after TPA treatment by indirect immunofluorescence (Fig. 2) . The characteristic punctate staining of large connexons at the cell membrane which was observed in untreated keratinocytes (Fig. 2a) was lost in TPA-treated cells (Fig. 2b ). An increase of cytoplasmic staining with perinuclear localization was observed after TPA treatment. While no attempt was made to quantify the signal strength, it was consistently observed that the intensity of immunofluorescence was greater in TPA-treated samples than in controls. The reason for this difference is not known, but several possibilities can be suggested. These include (i) the lack of detection of small gap junction plaques by immunofluorescence and/or (ii) different accessibility of epitopes in TPAtreated versus untreated samples.
More drastic effects on the a1 protein profile were observed with TPA at 100 ng/ml, which caused a dramatic shift of most, if not all, of this protein to the more slowly migrating 46-kDa species (Fig. 1A) . In contrast to the transient modification observed with 10 ng of TPA per ml, the 46-kDa form predominated even at the later time points (4 to 8 h). Similar to TPA at 10 ng/ml, the total amount of the a1 protein declined to barely detectable levels by 24 h. A second, more detailed time course of the response to TPA treatment at 100 ng/ml confirmed these results and revealed that the a1 protein shifted to the 46-kDa form as early as 5 min after TPA exposure (Fig. 1B) .
To determine whether the mobility differences of the various a1 species are due to phosphorylation, immunoprecipitated a1 protein from control and TPA-treated cells (100 ng of TPA per ml for 2 h) was digested with alkaline phosphatase and electrophoresed on a low-bisacrylamide gel (12.5% acrylamide-0. 10% bis). This gel system allows better separation of the various a1 forms. Alkaline phosphatase converted the 44-and 46-kDa species to the faster-migrating 42-kDa form present in control samples, and the migration of the 42-kDa form was not altered by phosphatase treatment (Fig. 3) . Addition of vanadate prevented the phosphatase from altering the mobility of the 46-kDa species (data not shown).
To identify the amino acid phosphorylated in response to TPA, the a1 protein was immunoprecipitated from 32p_ labelled cells and transferred to Immobilon membranes. No 32P-labelled 42-kDa species was observed in either TPAtreated or control cells, confirming that this was the nonphosphorylated form. The 46-kDa species induced by TPA was excised and subjected to phosphoamino acid analysis, which revealed phosphorylation exclusively on serine residues (Fig. 4A) . This result was confirmed by direct phosphoamino acid analysis of the a1 protein in crude gap junction preparations. Gap junctions, extracted by sodium hydroxide fractionation of 32P-labelled and unlabelled cells, were electrophoresed and transferred to an Immobilon membrane, and the unlabelled portion of the blot was incubated with a1 antibodies. Immune complexes were detected with 125I-labelled protein A and aligned with the portion of the blot containing the 32P-labelled samples. Regions of the blot corresponding to the 32P-labelled a1 protein from both control and TPA-treated samples were excised and subjected to phosphoamino acid analysis. The only phosphorylated amino acid detected was serine, and the amount of phosphorylated serine increased significantly upon TPA treatment ( Fig. 4B and C) . GJIC was measured by the scrape-loading-dye transfer technique (17) at various times after TPA treatment to determine whether early phosphorylation of a1 correlates with inhibition of junctional communication (Fig. 5) . Addition of 10 ng of TPA per ml resulted in a substantial decrease in GJIC by 1 h, which paralleled the appearance of the 46-kDa a1 species. Conversion of the phosphorylated a1 protein pattern to control levels by 8 h correlated with a substantial increase in junctional communication, even though GJIC was not restored to 100% of the control levels. In cells treated with 100 ng of TPA per ml, a1 phosphorylation was detected as early as 5 min posttreatment (Fig. 1B) and GJIC was already significantly reduced. By 2 h, a1 was maximally phosphorylated and GJIC reached its lowest level. Thus, phosphorylation of a1 may be directly responsible for inhibition of GJIC at early times after TPA treatment.
The P2 protein is expressed at rather low levels in primary keratinocytes. In contrast to that of a1, the electrophoretic mobility of P2 did not change after TPA treatment (Fig. 1A) TPA-treated samples (data not shown), suggesting that the 12 protein was not phosphorylated in response to TPA. The 12 protein levels seemed to increase to a maximum at 4 h after treatment with 10 ng of TPA per ml, or at 8 h after treatment with 100 ng/ml, and then decreased to undetectable levels by 24 h (Fig. 1A) . These results are consistent with RNA expression studies (see below) which showed modulation of 12 after addition of either 10 or 100 ng of TPA per ml by RNase protection analysis. Following treatment with 10 ng of TPA per ml, the level of a1 RNA was significantly reduced by 8 h (Fig. 6) . A similar a1 RNA profile was seen when cells were exposed to TPA at a higher concentration (100 ng/ml; Fig. 6 ; 5 p.g of total RNA, rather than 10 ,ug, was used in this analysis, yielding a lower basal a1 signal).
In the case of P2, the steady-state level of RNA continuously increased, reaching a peak at either 4 h in the presence of 10 ng of TPA per ml (Fig. 6 ) or 8 h in the presence of 100 ng of TPA per ml (Fig. 6) . Similar to the a, mRNA, the 12 message then declined to barely detectable levels by 24 h. These variations in RNA expression paralleled the protein profile and indicated that, in addition to inducing phosphorylation of a,, TPA modulated the steady-state levels of both the a1 and 02 gap junction transcripts.
Gap junction expression and modification following ras transformation. Transformation of mouse primary keratinocytes by the activated ras oncogene introduced via infection with HaSV results in partial disruption of the differentiation program of these cells in vitro (8, 56 ) and a tumorigenic phenotype in vivo (15, 36a, 45) . Since GJIC in these transformed keratinocytes is significantly reduced (70 to 80%; 12), the effect of ras transformation on the expression of gap junction RNA and protein was examined.
The concentrations of a1 mRNA and protein were only slightly reduced in HaSV-infected cells compared with those of control cultures infected with helper MoLV alone ( Fig. 7A and B). In contrast, the levels Of 02 mRNA and protein were greatly reduced in HaSV-infected keratinocytes, similar to the pattern observed after TPA treatment.
Transformation by ras also resulted in an altered pattern of phosphorylation of the a1 protein (Fig. 7B) . Whereas the a1 protein in MoLV-infected cells was present as the 42-and 44-kDa species, the al found in HaSV-infected cells was equally distributed among its three forms. This pattern closely resembled that observed in cells treated with TPA at 10 ng/ml. To identify the phosphorylated amino acid residue, the a1 gap junction protein was immunoprecipitated from 32P-labelled, ras-transformed keratinocytes. No 32p label was found in the 42-kDa a1 form, while both the 44 HaSV for 1 week. Infected cells were either untreated (-) or exposed to 10 ng of TPA per ml for 1 h (+). Gap junction proteins which were extracted by NaOH fractionation were subjected to immunoblot analysis as described in Materials and Methods.
was the only amino acid detected in both the 44-and 46-kDa a1 species ( Fig. 4D and E) . Treatment of ras-transformed keratinocytes with 10 ng of TPA per ml for 1 h caused, in addition to phosphorylation of a1 protein, a substantial reduction in the a1 concentration. The total level of a1 protein in TPA-treated, ras-transformed cells was much lower than that found in TPA-treated, MoLV-infected control cells (Fig. 7C) . Thus, the effects of ras and TPA on a1 expression were additive and these molecular events are consistent with synergistic inhibition of GJIC by these agents (12) . DISCUSSION In this report, we show that TPA treatment and ras transformation of mouse primary keratinocytes results in both phosphorylation of a1 protein and decreased expression of the a1 and P2 genes. These results provide a molecular explanation for the decrease in GJIC that ras and TPA cause in these primary cells and suggest a possible mechanism for the GJIC inhibition produced by these agents in other cell types.
Phosphorylation of a1 has been implicated in the regulation of gap junctional communication. Treatment of the mouse cell line C3H 10T1/2 with a synthetic retinoid, a potent inhibitor of experimental carcinogenesis, increased both GJIC and phosphorylation of a1 (at unidentified residues; 44). In a separate study, serine phosphorylation was shown to correlate with increased GJIC, as certain communication-deficient cell lines were unable to phosphorylate a1 on serine residues to generate the 46-kDa form (39) . The kinase(s) responsible for these modifications is not known. The fact that TPA-induced serine phosphorylation of a1 was associated with inhibition of GJIC, rather than an increase, suggests that the phosphorylated sites in TPA-treated cells are different from the sites associated with increased communication. An (30) . PKC may be directly responsible for TPA-induced phosphorylation of a1. Such PKC activity is consistent with the early time course of phosphorylation and the fact that a1 was entirely phosphorylated on serine residues. Several potential PKC modification sites are present in the carboxy terminus of the a1 protein (20) . Further, addition of PKC to electrically coupled cell pairs resulted in loss of junctional conductance (48) .
Treatment of keratinocytes with TPA at 10 ng/ml caused transient phosphorylation of a1 (1 to 2 h), which then returned to control levels (at 8 h). This correlates with the initial inhibition of GJIC (12), which is followed by an increase in junctional communication by 8 h. The fact that GJIC did not return to 100% of the control levels may be due to the presence of small amounts of the 46-kDa form of a1. Alternatively, the conformation of a1 after dephosphorylation may be altered, interfering with its ability to form functional channels.
In addition to a1, primary keratinocytes expressed the 2 gap junction protein at rather low levels. Our results suggest that the P2 protein is not modified by phosphorylation in TPA-treated keratinocytes. It has been previously shown that 2 is not phosphorylated in hepatocytes or by purified cyclic AMP-dependent protein kinase, PKC, or calcium/ calmodulin-dependent protein kinase 11 (46, 50 12 forms heteropolymeric channels (58) . If the a, and 12 proteins form such channels in keratinocytes, then even an increase in 12 expression may not be expected to compensate for the inactivated ae protein. It is interesting that both the a, and 12 products are utilized by skin in vivo (24, 42a) .
Expression of ao and 12 was repressed at the RNA level upon prolonged treatment with TPA. The kinetics of a1 and 12 repression differed markedly from that of the TPArepressible gene CEF-10 (47) . TPA treatment for 1 h induces PKC activity and suppresses CEF-10 expression (47) . By 24 h, TPA down regulates PKC and increases CEF-10 expression (47) . In contrast to CEF-10, down modulation of gap junction proteins occurs several hours after TPA treatment and appears to be indirectly linked to PKC activity. TPA induces a differentiation response in primary keratinocytes similar to that of calcium (13, 19, 22, 55, 57) , and calcium, like prolonged TPA treatment, suppresses gap junction expression (unpublished data). Thus, the effects of TPA on gap junction expression may result from induction of some aspects of keratinocyte differentiation.
The ras oncogene was previously shown to cause a 70 to 80% decrease in GJIC in primary keratinocytes and completely inhibit communication in synergism with TPA (12) . In this study, we found that ras, like TPA, induced seine phosphorylation of al and that the phosphorylation pattern resulting from ras transformation was similar to the pattern induced by 10 ng of TPA per ml. While it is not known which kinase(s) is activated by ras, one possible candidate is PKC, as ras has been shown to act through PKC-dependent (as well as PKC-independent) pathways (33, 52) . Like TPA, ras did not appear to induce modification of 12, but it caused substantial down modulation of its expression.
The effects of ras and TPA were additive. In ras-transformed cells treated with TPA, phosphorylation of the al protein increased and its expression was reduced to a level lower than that found in cells exposed to either agent alone. Such a rapid effect on a1 expression may be due to protein destabilization. However, decreased levels of a, mRNA 15 to 30 min after treatment of ras-transformed cells with TPA were also observed (unpublished data). Cooperation between ras and TPA has been shown both in vitro in focus formation of cells (14, 25) and in vivo in induction of skin tumors (6) . The additive effects of ras and TPA in blocking GJIC (12) via modulation of gap junction proteins may contribute to clonal expansion of initiated cells during neoplastic development.
